Physician profile
Daniel T Milton
NPI 1205896818
$231,052.17
in general payments reported to CMS, 2019-2025
48 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $39K · 2021: $19K · 2022: $32K · 2023: $66K · 2024: $37K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Travel and Lodging: $22K · Food and Beverage: $4,400 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,780.25 |
| Travel and Lodging | $21,813.92 |
| Food and Beverage | $4,400.46 |
| Education | $109.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $78,739.30 | 2019-2025 | Padcev, Cresemba |
| Seagen INC. | $60,852.76 | 2020-2023 | Padcev, Adcetris |
| Pfizer INC. | $41,383.19 | 2019-2025 | |
| Lilly USA, LLC | $26,929.79 | 2019-2023 | Retevmo |
| Merck Sharp & Dohme LLC | $16,346.66 | 2019-2024 | Keytruda |
| Mirati Therapeutics, INC. | $4,378.77 | 2023 | Krazati |
| Genzyme Corporation | $202.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $191.02 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $168.80 | 2019-2025 | Opdivo |
| Amgen INC. | $161.90 | 2020-2024 | Lumakras, Blincyto |
| Daiichi Sankyo INC. | $153.76 | 2022-2025 | Enhertu |
| Genentech, INC. | $127.05 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $121.65 | 2021-2025 | Airsupra, Enhertu, Tagrisso |
| Celgene Corporation | $121.32 | 2023-2025 | Reblozyl, Opdivo |
| Adc Therapeutics America, INC. | $91.59 | 2023 |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Milton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.